- IONS -1.88%
The Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) First-Quarter Results Are Out And Analysts Have Published New Forecasts
Yahoo Finance · 2 hours ago
Search results
1 day ago · Ionis Pharmaceuticals (IONS) reported $119 million in revenue for the quarter ended March 2024, representing a year-over-year decline of 9.2%.
- 40.16Add to watchlist-0.77 (-1.88%)At close:4:00 PM EDTWed. May 8, 202440.15 -0.01 (-0.02%)Pre mkt:8:00 AM EDTThu. May 9, 2024Nasdaq Real Time Price (USD) · Pre-Market Time
- Open40.57High40.80Low40.06
- Mkt Cap5.86BP/E (TTM)N/ADiv & YieldN/A & N/A
- Prev. Close40.9352 Wk. Low34.9952 Wk. High54.44
What analysts are sayingTop storiesRelated stocks
Ionis Innovation. The Ionis antisense pipeline. Our antisense technology platform has served as a springboard for drug discovery and realized hope for patients with unmet needs. Our broad, diverse pipeline has more than 40 potential first-in-class and/or best-in-class medicines designed to treat a broad range of diseases.
Ionis is guided by world-class scientists and business leaders whose passion to innovate is matched only by their commitment to deliver transformational medicines to patients who need them. ©1989 – 2024 Ionis Pharmaceuticals® is a registered trademark of Ionis Pharmaceuticals, Inc.
A perpetual and efficient innovation machine. Our platform technology has served as a springboard for drug discovery and realized hope for patients with unmet needs. Our broad, diverse pipeline has more than 40 first-in-class and/or best-in-class medicines designed to treat a broad range of diseases. Review our pipeline »
Mar 13, 2024 · CARLSBAD, Calif., March 13, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced positive results from a Phase 2 study of ION224, an investigational DGAT2 antisense inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), previously referred to as nonalcoholic steatohepatitis ...
Ionis’ antisense technology. With RNA as the target that forms the basis of our novel drug discovery platform, we are tackling the most difficult to treat diseases with a focus on neurology and cardiometabolic diseases.
Jan 8, 2024 · CARLSBAD, Calif., Jan. 8, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced highlights from the Company's 2023 achievements and previewed a number of important milestones expected in 2024.
